Thumbnail Image
Item

Ebola Vaccine Called 100% Effective

Authors
Kohn, David
Advisor
Date
2016-12-23
Embargo until
Language
Book title
Publisher
Peer Reviewed
Type
Article
Research Area
Jurisdiction
Collections
Center for Vaccine Development and Global Health
Show all metadata
Files
Thumbnail Image
EbolaVaccine_UMB2016.pdf
Adobe PDF, 308.13 KB
Other Titles
Ebola Vaccine Called One Hundred Percent Effective
See at
Abstract
Data Availibility
Data / Code Location
Table of Contents
Description
News release announcing the successful results of an experimental Ebola vaccine in a 2015 trial in Guinea, West Africa. Investigators from the UMB School of Medicine’s Center for Vaccine Development (CVD) and its field site in Mali participated in training field workers in the principles of Good Clinical Practice. The rVSV-ZEBOV vaccine manufactured by Merck, Sharpe & Dohme, was administered to 5,837 people in the project that was led by the World Health Organization (WHO). The results of the trial were published in the journal, Lancet (Vol. 389, no. 10068, Feb. 4, 2017).
Citations
Altmetric:
Series/Report No.
Sponsors
Rights/Terms
Keyword
rVSV-ZEBOV
 University of Maryland, Baltimore. Center for Vaccine Development (CVD)
 Hemorrhagic Fever, Ebola--prevention & control
 Ebola Vaccines--therapeutic use
 Guinea
 Merck Sharp & Dohme
Identifier to cite or link to this item
http://hdl.handle.net/10713/6972
Scopus Identifier
Embedded videos